52-Week efficacy in patients with moderate to severe psoriasis continued on apremilast or switched from etanercept: The LIBERATE study

被引：0
|
作者：
Reich, K. [1 ,2 ]
Papp, K. [3 ]
van de Kerkhof, P. [4 ]
Zhang, Z. [5 ]
Nograles, K. [5 ]
Soung, J. [6 ]
机构：
[1] SCIderm Res Inst, Hamburg, Germany
[2] Dermatol Hamburg, Hamburg, Germany
[3] Prob Med Res, Waterloo, ON, Canada
[4] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[5] Celgene Corp, Warren, NJ USA
[6] Southern Calif Dermatol, Santa Ana, CA USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [11] Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
    Reich, K.
    Gooderham, M.
    Bewley, A.
    Green, L.
    Soung, J.
    Petric, R.
    Marcsisin, J.
    Cirulli, J.
    Chen, R.
    Piguet, V.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (03) : 397 - 402
  • [12] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
    Reich, K.
    Gooderham, M.
    Green, L.
    Bewley, A.
    Zhang, Z.
    Khanskaya, I.
    Day, R. M.
    Goncalves, J.
    Shah, K.
    Piguet, V.
    Soung, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517
  • [13] Cost per responder of apremilast and etanercept in patients with moderate to severe plaque psoriasis using results from LIBERATE
    Tencer, Tom
    Clancy, Zoe
    Zhang, Frank
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB242 - AB242
  • [14] Efficacy and Safety of Apremilast through 104 Weeks in Subjects with Moderate to Severe Psoriasis Randomized to Placebo, Apremilast, or Etanercept Who Continued on or Switched to Apremilast after Week 16 in a Phase 3b Study
    Reich, Kristian
    Goodfield, Mark
    Green, Lawrence
    Nograles, Kristine
    Chen, Rongdean
    Levi, Eugenia
    Langley, Richard G. B.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [15] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 52-week results of the ESTEEM 2 Trial
    Paul, C.
    Gooderham, M.
    Cather, J.
    Poulin, Y.
    Girolomoni, G.
    Ferrandiz, C.
    Gottlieb, A. B.
    Mrowietz, U.
    Hu, Cc.
    Day, R. M.
    Richter, S.
    Crowley, J.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 63 - 63
  • [16] Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
    Umezawa, Yoshinori
    Asahina, Akihiko
    Imafuku, Shinichi
    Tada, Yayoi
    Sano, Shigetoshi
    Morita, Akimichi
    Sakurai, Shinya
    Hoshii, Naoki
    Tilt, Nicola
    Nakagawa, Hidemi
    DERMATOLOGY AND THERAPY, 2021, 11 (03) : 943 - 960
  • [17] Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
    Yoshinori Umezawa
    Akihiko Asahina
    Shinichi Imafuku
    Yayoi Tada
    Shigetoshi Sano
    Akimichi Morita
    Shinya Sakurai
    Naoki Hoshii
    Nicola Tilt
    Hidemi Nakagawa
    Dermatology and Therapy, 2021, 11 : 943 - 960
  • [18] Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL
    Gold, Linda Stein
    Bagel, Jerry
    Lebwohl, Mark
    Jackson, J. Mark
    Chen, Rongdean
    Goncalves, Joana
    Levi, Eugenia
    Duffin, Kristina Collis
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (02) : 221 - 228
  • [19] Effect of apremilast and etanercept on pruritus and health-related quality of life in patients with moderate to severe plaque psoriasis: Results from the LIBERATE study
    Green, Lawrence
    Thaci, Diamant
    Zhang, Zuoshun
    Goncalves, Joana
    Nograles, Kristine
    Nikkels, Arjen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB245 - AB245
  • [20] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis
    Kaur, M.
    Merola, J.
    Tatulych, S.
    Mamolo, C.
    Lan, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 81 - 81
12345